Approval Alert | Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.